Summary
Optimal use of hospital resources and intervention using suPAR for improving prognosis and care for patients with COVID-19
To optimize hospital resources, it is necessary to test which patients that can be sent home (mild outcome of infection) and which patients that should be admitted to hospital (high risk patients).
This will deliver on the tasks: 1) Identify patients that can safely cope with the infection at home and 2) Identify high risk patients early in the disease and 3) Select high-risk patients that may benefit of therapy.
But how can we identify low- or high-risk patients?
The suPARnostic test developed by ViroGates and CE/IVD approved for clinical use is highly prognostic marker for 30-day mortality.
Some hospitals have suPAR in routine clinical assessment of patient risk, and preliminary data support that suPAR levels can triage whether patients with COVID-19 will have a mild or a severe outcome of COVID-19 and thereby select which patients that could be discharged or admitted.
We aim to transfer manufacturing, upscale and implement the suPARnostic technology across hospitals in Europe to improve the risk stratification of COVID-19 patients and optimize hospital resources. We furthermore provide a test method that can identify high-risk patients that may benefit from experimental therapeutic interventions that may impact on outcome. The identification of patients in high risk of mortality (patients with high suPAR) provide a possibility to intervene.
To optimize hospital resources, it is necessary to test which patients that can be sent home (mild outcome of infection) and which patients that should be admitted to hospital (high risk patients).
This will deliver on the tasks: 1) Identify patients that can safely cope with the infection at home and 2) Identify high risk patients early in the disease and 3) Select high-risk patients that may benefit of therapy.
But how can we identify low- or high-risk patients?
The suPARnostic test developed by ViroGates and CE/IVD approved for clinical use is highly prognostic marker for 30-day mortality.
Some hospitals have suPAR in routine clinical assessment of patient risk, and preliminary data support that suPAR levels can triage whether patients with COVID-19 will have a mild or a severe outcome of COVID-19 and thereby select which patients that could be discharged or admitted.
We aim to transfer manufacturing, upscale and implement the suPARnostic technology across hospitals in Europe to improve the risk stratification of COVID-19 patients and optimize hospital resources. We furthermore provide a test method that can identify high-risk patients that may benefit from experimental therapeutic interventions that may impact on outcome. The identification of patients in high risk of mortality (patients with high suPAR) provide a possibility to intervene.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/961844 |
| Start date: | 01-08-2020 |
| End date: | 31-07-2022 |
| Total budget - Public funding: | 1 470 057,00 Euro - 884 990,00 Euro |
Cordis data
Original description
Optimal use of hospital resources and intervention using suPAR for improving prognosis and care for patients with COVID-19To optimize hospital resources, it is necessary to test which patients that can be sent home (mild outcome of infection) and which patients that should be admitted to hospital (high risk patients).
This will deliver on the tasks: 1) Identify patients that can safely cope with the infection at home and 2) Identify high risk patients early in the disease and 3) Select high-risk patients that may benefit of therapy.
But how can we identify low- or high-risk patients?
The suPARnostic test developed by ViroGates and CE/IVD approved for clinical use is highly prognostic marker for 30-day mortality.
Some hospitals have suPAR in routine clinical assessment of patient risk, and preliminary data support that suPAR levels can triage whether patients with COVID-19 will have a mild or a severe outcome of COVID-19 and thereby select which patients that could be discharged or admitted.
We aim to transfer manufacturing, upscale and implement the suPARnostic technology across hospitals in Europe to improve the risk stratification of COVID-19 patients and optimize hospital resources. We furthermore provide a test method that can identify high-risk patients that may benefit from experimental therapeutic interventions that may impact on outcome. The identification of patients in high risk of mortality (patients with high suPAR) provide a possibility to intervene.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Search
